Clinical Trial Search

Primary: Number Of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs Leading To Discontinuation — 460; 7; 41 Participants

Primary: PrEP Retention — 100 participants

Primary: Mean Weekly Log-transformed Seizure Frequency During Weeks 1 Through 10 — 5.20; 10.77 log[seizures per week]

Primary: Percentage of Participants With Endoscopic Improvement During Induction Period — 18.0 percentage of participants

Primary: Assess the Safety of the Study Drug by Calculating the Proportion of Patients Who Experience Grade 4 or 5 Study Drug Related Adverse Events, as Assessed by CTCAE v 4.03…

Primary: Safety Endpoint: Number of Subjects With SAEs, AEs Leading to Withdrawal From the Study, NOCDs, AESIs and Medically Attended AEs. — 7; 4; 0; 0 Participants

Primary: Proportion of Subjects Achieving at Least 2-point Decrease in Hyperhidrosis Disease Severity Scale (HDSS) From Baseline to Week 4 — 35; 37; 29; 36 Participants

Primary: Reduction in Migraine Days — -3.8; -1.1 Migraine days per month — p=<0.05

Primary: Mean Change From Baseline at 12 Weeks of MN-001 Treatment on Cholesterol Efflux Capacity — -0.013 percentage of cholesterol

Primary: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm (Co-primary Endpoint) — 95.0; 91.0 percentage of…

Primary: Number of Participants Identifying Themes on SweetMama Features — 9; 11; 11; 2 Participants

Primary: Change in Inferior Corneal Fluorescein Staining Score Post Controlled Adverse Environment (Post-Controlled Adverse Environment (CAE)) — -0.57; -0.44 scores on a scale…

Primary: Overall Quality of Vision Score — 56.9 Units on a scale

Primary: Number of Participants Who Demonstrated at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume — 3; 5 Participants

Primary: Overall Survival — 4.8 months